Table 2. Comparison of clinical characteristics between the subjects with erosive esophagitis and the control group.
| EE (n = 1,262) |
Control (n = 3,254) | P value | |
|---|---|---|---|
| Age, mean±SD (years) | 52.6±9.4 | 52.7±10.3 | 0.5524 |
| Age group | 0.0037 | ||
| ≤39 years (%) | 7.8 | 9.5 | |
| 40–59 years (%) | 69.3 | 64.0 | |
| ≥60 years (%) | 22.9 | 26.5 | |
| Male (%) | 83.8 | 61.7 | <0.0001 |
| BMI, mean±SD (kg/m2) | 24.3±3.6 | 22.7±3.1 | <0.0001 |
| BMI ≥25 kg/m2 (%) | 37.0 | 20.3 | <0.0001 |
| Current smoking (%) | 24.9 | 14.8 | <0.0001 |
| Alcohol consumption ≥20 g /day (%) | 38.9 | 23.7 | <0.0001 |
| Sleep shortage (%) | 30.0 | 28.4 | 0.3001 |
| Exercise shortage (%) | 65.1 | 60.8 | 0.0076 |
| Irregular meal time (%) | 22.7 | 19.2 | 0.0074 |
| Experiencing high levels of stress (%) | 28.0 | 20.6 | <0.0001 |
| Feeling depressed (%) | 7.1 | 5.5 | 0.0419 |
| Kyphosis diagnosed by questionnaire (%) | 0.71 | 0.34 | 0.0885 |
| STAI score, mean±SD | 41.1±9.9 | 40.0±9.5 | 0.0004 |
| High STAI score (%) | 37.4 | 31.3 | <0.0001 |
| Hiatal hernia (%) | 48.3 | 24.4 | <0.0001 |
| Endoscopic Barret’s mucosa ≥10 mm (%) | 4.5 | 1.4 | <0.0001 |
| Atrophic gastritis (%) | 24.5 | 40.8 | <0.0001 |
| Use of NSAIDs (%) | 1.7 | 1.2 | 0.2561 |
| Use of low-dose aspirin (%) | 0.87 | 1.4 | 0.1636 |
| Use of Ca antagonists (%) | 12.5 | 9.0 | 0.0005 |
| Use of ARB (%) | 10.1 | 7.3 | 0.0018 |
| Use of statins (%) | 10.7 | 9.3 | 0.1678 |
| Use of oral hypoglycemic agents (%) | 5.1 | 3.0 | 0.0010 |
| Use of bisphosphonate (%) | 0.16 | 0.40 | 0.2606 |
| Use of gastromucoprotective agents (%) | 2.6 | 2.0 | 0.2270 |
EE, erosive esophagitis; SD, standard deviation; BMI, body mass index; STAI, State-Trait Anxiety Inventory; NSAIDs, non-steroidal anti-inflammatory drugs; Ca, calcium; ARB, angiotensin II receptor blocker.